Cerus Corporation to Release First Quarter 2023 Financial Results on May 4, 2023

Rhea-AI Summary

Cerus Corporation (CERS) will release its first quarter 2023 financial results on May 4, 2023, after market close. A conference call and webcast will follow at 4:30 P.M. ET for management to discuss results and provide an outlook.

The company focuses on safeguarding the global blood supply with its INTERCEPT Blood System, which is the only pathogen reduction system approved by both CE and FDA for platelets and plasma. The red blood cell system is under review in Europe and in late-stage clinical development in the US. Additionally, the INTERCEPT system for Cryoprecipitation is approved in the US for producing therapeutic products addressing bleeding issues related to fibrinogen deficiency.

Positive

• INTERCEPT Blood System is the only pathogen reduction system approved by both CE and FDA for platelets and plasma.
• The INTERCEPT red blood cell system is under regulatory review in Europe and in late-stage clinical development in the US.
• Approval for the INTERCEPT Blood System for Cryoprecipitation in the US, increasing product offerings.

Negative

• None.

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2023 financial results will be released on Thursday, May 4, 2023, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.

To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event.

A replay will be available on Cerus’ website and will be available approximately three hours after the call through May 18, 2023.

ABOUT CERUS

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of INTERCEPT Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230420005355/en/

Jessica Hanover – Vice President, Corporate Affairs

Cerus Corporation

925-288-6137

Source: Cerus Corporation

FAQ

When will Cerus Corporation release its Q1 2023 financial results?

Cerus Corporation will release its Q1 2023 financial results on May 4, 2023.

What time is the Cerus Corporation conference call scheduled?

The conference call is scheduled for 4:30 P.M. ET on May 4, 2023.

How can I access the Cerus Corporation financial results presentation?

The presentation can be accessed on Cerus Corporation's Investor Relations page at http://ir.cerus.com.

What products does Cerus Corporation offer?

Cerus Corporation offers the INTERCEPT Blood System for pathogen reduction in blood components and has various products in development for blood safety.